Alirokumab in the practice of a multidisciplinary outpatient hospital: results of an open, noncomparative prospective study

Alirokumab in the practice of a multidisciplinary outpatient hospital: results of an open, noncomparative prospective study

Aim. Evaluation of efficacy and safety of alirocumab in patients with atherogenic dyslipidemia in real clinical practice.Materials and methods. Patients with atherogenic dyslipidemia and failure to achieve target lipid levels were included in a prospective, non-comparative study. For the final analy...

Full description

Bibliographic Details
Main Authors:	A. O. Bueverov, P. O. Bogomolov, A. A. Kucherov, V. E. Syutkin
Format:	Article
Language:	Russian
Published:	Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) 2021-04-01
Series:	Сеченовский вестник
Subjects:	atherogenic dyslipidemia treatment alirocumab lipoprotein (a) liver transplantation
Online Access:	https://www.sechenovmedj.com/jour/article/view/297

Similar Items

Diabetic Dyslipidemia: Current Concepts in Pathophysiology and Management
by: Debasish Chaudhury, et al.
Published: (2018-01-01)

About atypical dyslipidemia variants in myocardial infarction and unstable angina
by: B. M. Lipovetsky
Published: (2009-10-01)

PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders
by: O. L. Barbarash, et al.
Published: (2020-09-01)

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies
by: Kausik K. Ray, et al.
Published: (2019-11-01)

The mixed benefit of low lipoprotein(a) in type 2 diabetes
by: Michel P. Hermans, et al.
Published: (2017-09-01)

Safety and efficacy of alirocumab: A meta analysis of 12 randomized controlled trials
by: Ajay K Shukla, et al.
Published: (2019-01-01)

Hypolipidemic therapy in patients with non-alcoholic fatty liver disease
by: L. B Lazebnik, et al.
Published: (2010-03-01)

Evaluation of Dyslipidemia, Lipid Ratios and Atherogenic Index as Cardiovascular Risk Factors in Overt and Subclinical Hypothyroid Patients
by: Shivakrishna G, et al.
Published: (2013-07-01)

Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON
by: Alberto J. Lorenzatti, et al.
Published: (2021-04-01)

Correction of atherogenic dyslipidemia with honey, pollen and bee bread in patients with different body mass
by: Valentina Ivanovna Kas'yanenko, et al.
Published: (2011-08-01)

Pathophysiological rationale for the results of atherogenic dyslipidemia simulation in rats
by: V. G. Banzaraksheev
Published: (2016-05-01)

Evaluation of diagnostic performance of serum copeptin in correlation with dyslipidemia in Obesed and Non-Obesed type 2 diabetes mellitus (T2DM)
by: Adedeji David Atere, et al.
Published: (2020-10-01)

Anti-Atherosclerotic Potential of Aqueous Extract of Cinnamomum zeylanicum Bark against Glucocorticoid Induced Atherosclerosis in Wistar Rats
by: IM Nagendra Nayak, et al.
Published: (2017-05-01)

A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
by: Rana K, et al.
Published: (2019-09-01)

Lipoprotein-Cholesterol Fractions in Marginalized Roma versus Majority Population
by: Beáta Hubková, et al.
Published: (2018-01-01)

Lysosomal acid lipase deficiency – early diagnosis is the key
by: Strebinger G, et al.
Published: (2019-05-01)

Waist Circumference as a Preventive Tool of Atherogenic Dyslipidemia and Obesity-Associated Cardiovascular Risk in Young Adults Males: A Cross-Sectional Pilot Study
by: Alberto Hernández-Reyes, et al.
Published: (2020-12-01)

Dieta aterogénica y alteración de los índices de riesgo cardiovascular
by: Silvina Cuartas, et al.

Atherogenic indices in clinical practice and biomedical research: A short review
by: Hussein Abid, et al.
Published: (2021-06-01)

Kompleksnaya terapiya pri aterogennoydislipidemii i nealkogol'noy zhirovoybolezni pecheni
by: Elizaveta Andreevna Cherkashova, et al.
Published: (2011-03-01)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
by: Ioanna Gouni-Berthold, et al.
Published: (2014-12-01)

On the atherogenicity of triglyceride-rich lipoproteins and novel markers for the assessment of their atherogenic potentials
by: Alaupovic Petar
Published: (2002-07-01)

An association of hyperglycemia with plasma malondialdehyde and atherogenic lipid risk factors in newly diagnosed Type 2 diabetic patients
by: Suchitra Mustur Manohar, et al.
Published: (2013-01-01)

Comparative study of lipid profile and lipid indices in stroke patients and healthy subjects
by: Eilene Basu, et al.
Published: (2021-04-01)

Atherogenic index of plasma in highly active antiretroviral therapy-naïve patients with human immunodeficiency virus infection in Southeast Nigeria
by: Cajetan C Onyedum, et al.
Published: (2014-01-01)

The content of adipokines in women with hypothyroidism and type 2 diabetes mellitus
by: A. F. Verbovoy, et al.
Published: (2021-01-01)

Lipid profile, atherogenic indices, and their relationship with epicardial fat thickness and carotid intima–media thickness in celiac disease
by: Zuhal Çalışkan, et al.
Published: (2019-09-01)

Atherogenic Index of Plasma in Obstructive Sleep Apnoea
by: Andras Bikov, et al.
Published: (2021-01-01)

Cholesterol lipoproteins and prevalence of dyslipidemias in urban Asian Indians: A cross sectional study
by: Soneil Guptha, et al.
Published: (2014-05-01)

DYSLIPIDAEMIA IN CHILDREN ON DIALYSIS AND AFTER KIDNEY TRANSPLANTATION
by: S. V. Baiko
Published: (2017-12-01)

Systemic MCPIP1 deficiency in mice impairs lipid homeostasis
by: Joshua Moody, et al.
Published: (2020-04-01)

Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans
by: Burza Maria A, et al.
Published: (2011-06-01)

Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease
by: A. E. Nikitin, et al.
Published: (2020-03-01)

Acute changes in blood lipid profiles and metabolic risk factors in collegiate elite taekwondo athletes after short-term de-training: a prospective insight for athletic health management
by: Yu-Chi Sung, et al.
Published: (2017-07-01)

Cross-sectional study of pattern of Dyslipidemia and Prevalence of Atherogenic Diabetic Dyslipidemia in newly detected Diabetic patients
by: Vinay Krishnamurthy, et al.
Published: (2019-10-01)

Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study
by: Nasir H. Bhanpuri, et al.
Published: (2018-05-01)

Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
by: Julian P. Halcox, et al.
Published: (2017-06-01)

Dyslipidemia among Patients with End Stage Renal Disease on Maintenance Hemodialysis
by: Mohammed Ghazi Abdulhadi, et al.
Published: (2018-07-01)

Cardiovascular risk profile of patients with atherogenic dyslipidemia in middle age Lithuanian population
by: Sandra Kutkiene, et al.
Published: (2018-09-01)

Atherogenic index and coronarian risk – comparative assessment regarding the particularities of chronic autoimmune thyroiditis presence
by: Seceleanu Mihaela, et al.
Published: (2015-08-01)